Liquidia Corporation (NASDAQ:LQDA – Get Free Report) has received an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $75.23.
LQDA has been the subject of several research reports. Bank of America set a $54.00 price objective on Liquidia and gave the company a “neutral” rating in a report on Wednesday, November 11th. Royal Bank Of Canada set a $65.00 target price on Liquidia in a research note on Thursday, October 15th. Wells Fargo & Company upped their price target on Liquidia from $33.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 11th. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Finally, Wedbush set a $58.00 price target on Liquidia in a research note on Friday, October 2nd.
View Our Latest Analysis on Liquidia
Insiders Place Their Bets
Institutional Trading of Liquidia
A number of institutional investors have recently modified their holdings of LQDA. The Manufacturers Life Insurance Company grew its position in shares of Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after purchasing an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Liquidia during the 2nd quarter worth about $29,694,000. Seven Fleet Capital Management LP lifted its holdings in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Liquidia during the 2nd quarter worth about $1,236,000. Finally, Bank of America Corp DE lifted its holdings in Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.
Liquidia Price Performance
LQDA opened at $56.37 on Tuesday. The firm has a market cap of $5.08 billion, a P/E ratio of -45.83, a PEG ratio of 1.39 and a beta of 0.40. The firm has a 50-day moving average of $48.72 and a 200 day moving average of $54.82. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 1.02. Liquidia has a fifty-two week low of $22.31 and a fifty-two week high of $93.61.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($2.64) EPS for the quarter, missing the consensus estimate of $0.96 by ($3.60). The company had revenue of $225.30 million during the quarter, compared to the consensus estimate of $214.18 million. Liquidia had a positive return on equity of 264.65% and a negative net margin of 15.15%. The business’s revenue was up 314.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) EPS. On average, research analysts expect that Liquidia will post -0.25 EPS for the current year.
Liquidia Company Profile
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.
Recommended Stories
- Five stocks we like better than Liquidia
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
